🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Oral vs. Intravenous Hydration to Prevent Contrast-Associated Acute Kidney Injury in the ED

RecruitingNAAges 18 Years - anyAllGaziosmanpasa Research and Education Hospital
NCT07459413 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study is planned to be conducted by emergency physicians between November 7, 2025, and December 7, 2026. Inclusion and Exclusion Criteria The study will include adult patients aged 18 years and older who are considered at risk for Contrast-Associated Acute Kidney Injury (CA-AKI), with an estimated Glomerular Filtration Rate (eGFR) between 15-59 ml/min/1.73 m², a clinical indication for contrast-enhanced CT, and who have provided signed informed consent. Exclusion criteria are as follows: Pregnant women. Patients with a known contrast media allergy. Contrast media exposure within the last 72 hours. End-stage renal disease (ESRD) with eGFR \<15 ml/min/1.73 m² or those receiving dialysis. Patients with clinical decompensated heart failure. Patients for whom oral intake is contraindicated or not tolerated. Randomization and Interventions Prior to randomization, the oral intake

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients aged 18 years and older. * Patients with an estimated Glomerular Filtration Rate (eGFR) between 15-59 mL/min/1.73 m². * Patients undergoing contrast-enhanced computed tomography (CT) in the emergency department. * Patients who have provided written informed consent. Exclusion Criteria: * Pregnant women. * Patients with end-stage renal disease (ESRD) receiving dialysis or those with an eGFR \<15 mL/min/1.73 m². * Patients presenting with decompensated heart failure. * Patients with a known allergy to iodinated contrast media. * Patients with contrast media exposure within the last 72 hours. * Patients for whom oral intake is contraindicated or who cannot tolerate oral intake
💊

What it tests

  • Water
  • %0,9 NaCl
📍

Where

1 site
Gaziosmanpasa Training and Research Hospital
Istanbul, Turkey (Türkiye)
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy